文献速递神经核医学肿瘤 PET/CT

[68Ga]Ga-DOTA-JR11 PET/CT在脑膜瘤患者中的价值:与MRI对比

The usefulness of [68 Ga]Ga-DOTA-JR11 PET/CT in patients with meningioma: comparison with MRI.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-09-08

前瞻性纳入2021年8月至2022年10月疑似新发或复发脑膜瘤患者36例,比较[68Ga]Ga-DOTA-JR11 PET/CT与增强MRI的诊断效能。脑膜瘤组SUVmax和TBR均显著高于其他肿瘤组,PET在初诊组较MRI有24%的增量诊断价值,两者总体诊断效能无显著差异。

要点

  • 脑膜瘤组[68Ga]Ga-DOTA-JR11摄取显著高于其他肿瘤组(SUVmax 13.6±7.7 vs 5.2±3.0,P<0.001)。
  • PET/CT与增强MRI对全部36例患者的诊断效能无统计学显著差异(P=0.45)。
  • 在颅底脑膜瘤中,PET对垂体受累和骨受累的判定较MRI更明确。

核心结论

  • [68Ga]Ga-DOTA-JR11 PET/CT图像质量高,在检测脑膜瘤及评估垂体、骨受累方面表现出理想的诊断效能。
  • 该研究为[68Ga]Ga-DOTA-JR11 PET/CT作为增强MRI的补充影像手段用于脑膜瘤评估提供了有价值的证据。

研究设计与样本

  • 前瞻性研究,纳入2021年8月至2022年10月疑似新发或复发、位于复杂部位或影像不典型的脑膜瘤患者。
  • 所有患者均接受增强MRI、[68Ga]Ga-DOTA-JR11 PET/CT和组织病理学评估。
  • 共36例患者(年龄50.0±13.0岁,女性20例),其中32例经组织病理学确诊为脑膜瘤,4例为其他肿瘤。

主要发现

  • 脑膜瘤患者[68Ga]Ga-DOTA-JR11摄取显著高于其他肿瘤患者(SUVmax:13.6±7.7 vs 5.2±3.0,P<0.001;TBR:64.2±27.7 vs 25.0±18.9,P=0.001)。
  • [68Ga]Ga-DOTA-JR11 PET/CT检出31例脑膜瘤,增强MRI在25例初诊中检出17例、在11例复发肿瘤中检出11例。
  • 在初诊组中,[68Ga]Ga-DOTA-JR11 PET较MRI的增量诊断价值为24%(6/25)。
  • 全部36例患者中,PET与MRI的诊断效能无统计学显著差异(P=0.45)。
  • 颅底脑膜瘤中,PET对垂体受累给出更明确诊断(受累12例、未受累12例),MRI为受累8例、可能受累6例、可能未受累6例、未受累4例;病理证实的14例骨受累中PET全部检出,MRI仅检出11例。

临床怎么用

  • 研究结论认为[68Ga]Ga-DOTA-JR11 PET/CT可作为增强MRI的补充影像手段用于脑膜瘤评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Clinical studies of PET imaging using SSTR2 agonists have demonstrated high accuracy and correlation with SSTR2 expression in meningiomas. However, the usefulness of the SSTR2 antagonist with [68 Ga]Ga-DOTA-JR11 is uncertain. To evaluate the diagnostic performance of [68 Ga]Ga-DOTA-JR11 PET/CT and to clarify tumor characteristics in patients with suspected meningiomas. MATERIALS AND METHODS: Patients with suspected de novo or recurrent meningioma in complex locations or atypical images were enrolled from August 2021 to October 2022 in prospective study. All patients underwent contrast-enhanced MRI (CE-MRI), [68 Ga]Ga-DOTA-JR11 PET/CT, and histopathological evaluation. Tumor uptake of [68 Ga]Ga-DOTA-JR11 was measured by SUVmax and tumor-endocranium ratio (TBR). Diagnostic performance was compared between PET and MRI. RESULTS: Of 36 (50.0 ± 13.0 years of age, 20 women) patients, 32 were histopathologically confirmed meningiomas and four with other tumors. [68 Ga]Ga-DOTA-JR11 uptake was significantly higher in meningioma patients than in those with other tumors (SUVmax: 13.6 ± 7.7 vs. 5.2 ± 3.0, P < 0.001; TBR: 64.2 ± 27.7 vs. 25.0 ± 18.9, P = 0.001). [68 Ga]Ga-DOTA-JR11 PET/CT detected 31 meningiomas, while CE-MRI detected 17 meningiomas of 25 initial diagnosis and 11 recurrent tumors; [68 Ga]Ga-DOTA-JR11 PET had an incremental diagnostic value of 24% (6/25) over MRI in the group of initial diagnosis. There was no statistically significant difference in diagnostic efficacy between PET and MRI (P = 0.45) for all 36 patients. In skull base meningiomas, PET provided a more definitive diagnosis of pituitary involvement (in 12, not in12), compared to MRI (in eight, possible in six, possible not in six, not in four). PET revealed bone involvement in all 14 patients proven by pathology, while MRI identified only 11. CONCLUSIONS: [68 Ga]Ga-DOTA-JR11 PET/CT provided high image quality and presented an ideal diagnostic performance in detecting meningioma and evaluating the involvement of the pituitary and bone. The study provides valuable evidence for the use of [68 Ga]Ga-DOTA-JR11 PET/CT as a complementary imaging modality to CE-MRI in the evaluation of meningiomas.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wang P, Liu S, Li X, et al. The usefulness of [68 Ga]Ga-DOTA-JR11 PET/CT in patients with meningioma: comparison with MRI. Eur J Nucl Med Mol Imaging. 2023. PMID: 37682301. doi:10.1007/s00259-023-06391-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。